Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07177417 · ClinicalTrials.gov registry record · Phase 4
Characterizing the Human Airway Immune Response to FluMist Vaccination
A Phase 4 study of Healthy Young Adults and Influenza Vaccines, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07177417: Recruiting Phase 4 study of Healthy Young Adults and Influenza Vaccines, sponsored by Washington University School of Medicine.
NCT07177417 is a Phase 4 study of Healthy Young Adults and Influenza Vaccines that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 30 participants, below the 66-participant average among 4 other Healthy Young Adults trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07177417, a Phase 4 study of Healthy Young Adults and Influenza Vaccines, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to measure the immune response in the blood, nose, and lungs after participants receive either the FDA-approved inactivated influenza vaccine or the FDA-approved intranasal FluMist vaccine. The study will evaluate immune responses in groups of healthy, non-pregnant, volunteers between the ages of 18 and 40. The main purpose of the study is to measure the change in influenza vaccine-specific antibodies in the lower lungs and nose between vaccination and 14 days after participants receive the vaccine. All participants will be randomized to receive one of the two seasonal flu vaccines and will have blood and back of the nose swabs collected throughout the study. Some study participants will choose to undergo optional bronchoscopy procedures and will be included in the part of the study looking at lower lung immune responses.
Primary Outcome
Measure the change in influenza vaccine strain-specific hemagglutinin and neuraminidase antibody titers found at the upper and lower airway mucosal surface between day 0 and day 14 after administration of FluMist intranasal influenza vaccination versus standard dose trivalent IIV using ELISA.
Conditions Studied
Interventions
- BIOLOGICAL FluMist
- BIOLOGICAL inactivated influenza vaccine
- PROCEDURE bronchoscopy
Study Locations (1)
Missouri
- Washington University in Saint Louis School of Medicine Emergency Care and Research Core - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2028-11 |
| Phase | Phase 4 |
What NCT07177417 shows while recruiting
NCT07177417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 66-participant average among 4 other Healthy Young Adults trials with a reported enrollment target (55% lower).
The record links to 3 conditions, with Healthy Young Adults appearing as the primary indexed condition, and to 3 interventions - of which FluMist is the first listed.
NCT07177417 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07177417 about?
NCT07177417 is a clinical study titled "Characterizing the Human Airway Immune Response to FluMist Vaccination". The goal of this clinical trial is to measure the immune response in the blood, nose, and lungs after participants receive either the FDA-approved inactivated influenza vaccine or the FDA-approved intranasal FluMist vaccine. The study will evaluate immune responses in groups of healthy, non-pregnant...
What is the current status of trial NCT07177417?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-09-09. Estimated completion is 2028-11.
What conditions does trial NCT07177417 study?
This clinical trial studies the following conditions: Healthy Young Adults, Influenza Vaccines, Influenza Vaccine Response.
What interventions are being tested in trial NCT07177417?
The interventions under investigation include: FluMist (BIOLOGICAL), inactivated influenza vaccine (BIOLOGICAL), bronchoscopy (PROCEDURE).
Who is sponsoring clinical trial NCT07177417?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07177417 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Young Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Noninvasive Vagus Nerve Stimulation (VNS) for Neuromotor Adaptations
COMPLETED · NA
-
Campus Life Study: Harnessing Generativity Among Young Adults
COMPLETED · NA
-
Remote Limb Ischemic Conditioning to Enhance Learning and Muscle Strength in Healthy Young Adults
COMPLETED · Phase 1
-
Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI